Effects of high-frequency stimulation of the internal pallidal segment on neuronal activity in the thalamus in parkinsonian monkeys.
Deep brain stimulation of the internal globus pallidus (GPi) is a major treatment for advanced Parkinson's disease. The effects of this intervention on electrical activity patterns in targets of GPi output, specifically in the thalamus, are poorly understood. The experiments described here examined these effects using electrophysiological recordings in two Rhesus monkeys rendered moderately parkinsonian through treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), after sampling control data in the same animals. Analysis of spontaneous spiking activity of neurons in the basal ganglia-receiving areas of the ventral thalamus showed that MPTP-induced parkinsonism is associated with a reduction of firing rates of segments of the data that contained neither bursts nor decelerations, and with increased burst firing. Spectral analyses revealed an increase of power in the 3- to 13-Hz band and a reduction in the γ-range in the spiking activity of these neurons. Electrical stimulation of the ventrolateral motor territory of GPi with macroelectrodes, mimicking deep brain stimulation in parkinsonian patients (bipolar electrodes, 0.5 mm intercontact distance, biphasic stimuli, 120 Hz, 100 μs/phase, 200 μA), had antiparkinsonian effects. The stimulation markedly reduced oscillations in thalamic firing in the 13- to 30-Hz range and uncoupled the spiking activity of recorded neurons from simultaneously recorded local field potential (LFP) activity. These results confirm that oscillatory and nonoscillatory characteristics of spontaneous activity in the basal ganglia receiving ventral thalamus are altered in MPTP-induced parkinsonism. Electrical stimulation of GPi did not entrain thalamic activity but changed oscillatory activity in the ventral thalamus and altered the relationship between spikes and simultaneously recorded LFPs.
Yerkes National Primate Research Center, Emory University, Atlanta, Georgia.|Udall Center of Excellence in Parkinson's Disease Research, Emory University, Atlanta, Georgia.
Stefan
S
Kammermeier
Yerkes National Primate Research Center, Emory University, Atlanta, Georgia.|Udall Center of Excellence in Parkinson's Disease Research, Emory University, Atlanta, Georgia.
Damien
D
Pittard
Yerkes National Primate Research Center, Emory University, Atlanta, Georgia.|Udall Center of Excellence in Parkinson's Disease Research, Emory University, Atlanta, Georgia.
Ikuma
I
Hamada
Yerkes National Primate Research Center, Emory University, Atlanta, Georgia; twichma@emory.edu.|School of Medicine, Department of Neurology, Emory University, Atlanta, Georgia; and.|Udall Center of Excellence in Parkinson's Disease Research, Emory University, Atlanta, Georgia.
Thomas
T
Wichmann
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology; D000200:Action Potentials / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D046690:Deep Brain Stimulation / Q000379:methods*; D004195:Disease Models, Animal; D004569:Electroencephalography; D005071:Evoked Potentials / Q000187:drug effects; D005917:Globus Pallidus / Q000166:cytology / Q000502:physiology*; D008253:Macaca mulatta; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D009498:Neurotoxins / Q000633:toxicity; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D013788:Thalamus / Q000473:pathology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D009498:Neurotoxins; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase
deep brain stimulation; monkey; parkinsonism
Front Syst Neurosci. 2011 May 13;5:30
21625611
Neuron. 2012 Dec 6;76(5):1030-41
23217750
Nat Rev Neurosci. 2007 Aug;8(8):623-35
17637800
Neurotherapeutics. 2008 Apr;5(2):294-308
18394571
J Neurophysiol. 2014 Nov 15;112(10):2580-96
25143541
Neuroscience. 2000;96(3):549-64
10717435
J Neurosci. 2009 Jun 17;29(24):7797-802
19535591
Brain Res Bull. 2009 Feb 16;78(2-3):60-8
18805468
Eur Neuropsychopharmacol. 2010 Aug;20(8):519-34
20471808
J Neurophysiol. 2005 Jun;93(6):3094-101
15703231
J Neurosci. 2004 Aug 18;24(33):7410-9
15317866
J Neurosci. 2008 Jun 11;28(24):6165-73
18550758
J Neurosci. 2001 Feb 1;21(3):1033-8
11157088
Curr Opin Neurobiol. 2015 Apr;31:72-80
25233254
J Neurosci. 2004 Jul 21;24(29):6417-26
15269251
Brain Res. 1996 Dec 2;742(1-2):25-33
9117401
Neurosci Biobehav Rev. 2008;32(3):388-407
17706780
J Neurophysiol. 2006 Apr;95(4):2120-33
16371459
Eur J Neurosci. 2012 Jul;36(2):2213-28
22805066
J Neurophysiol. 2013 Dec;110(12):2792-805
24068758
Neurobiol Dis. 2012 Jan;45(1):583-90
22001603
J Clin Neurosci. 2007 Mar;14(3):208-15
17150360
J Neurosci. 2007 Jan 3;27(1):124-31
17202479
J Neurosurg. 2005 Dec;103(6):956-67
16381181
Neuroscience. 2000;101(4):993-9
11113348
Prog Biophys Mol Biol. 1995;64(2-3):237-78
8987386
J Neurophysiol. 1971 May;34(3):414-27
4997823
Exp Neurol. 2009 Sep;219(1):359-62
19409895
Chin Med J (Engl). 2010 Mar 20;123(6):695-701
20368089
Front Syst Neurosci. 2011 Jun 21;5:50
21734868
Neuroscience. 2006;137(2):367-72
16360282
Ann Neurol. 2015 Nov;78(5):742-50
26290353
Eur J Neurosci. 2014 Jun;39(11):1951-9
24890470
Front Neuroanat. 2015 Feb 05;9:5
25698937
Neurobiol Dis. 2015 Mar;75:177-85
25576395
J Neurosci. 2014 Nov 26;34(48):15836-50
25429126
Parkinsonism Relat Disord. 2015 Jun;21(6):597-602
25842261
J Neurophysiol. 2009 Apr;101(4):1941-60
19164104
Trends Neurosci. 2004 Sep;27(9):520-7
15331233
J Neurophysiol. 1985 Apr;53(4):926-39
3998798
Eur J Neurosci. 2003 Jun;17(11):2388-400
12814370
J Neurophysiol. 2015 Aug;114(2):825-34
26084905
Brain Res. 1991 Mar 8;543(1):123-38
2054667
Clin Neuropharmacol. 2000 Jul-Aug;23(4):208-11
11020125
Exp Neurol. 2006 Jan;197(1):244-51
16289053
Philos Trans R Soc Lond B Biol Sci. 2002 Dec 29;357(1428):1869-76
12626020
J Neurol Neurosurg Psychiatry. 2011 May;82(5):569-73
20935326
Clin Neurophysiol. 2006 Dec;117(12):2691-702
17029953
Science. 2009 Apr 17;324(5925):354-9
19299587
J Neurosci. 2005 Feb 9;25(6):1523-31
15703406
J Neurophysiol. 2007 Dec;98(6):3525-37
17928554
Front Syst Neurosci. 2014 Jan 30;8:5
24523677
J Neurophysiol. 2015 Apr 1;113(7):2537-48
25652922
Cereb Cortex. 2011 Jun;21(6):1362-78
21045003
J Neurosci Methods. 2000 May 15;98(1):57-62
10837871
J Neurosci. 2007 Mar 7;27(10):2525-38
17344390
J Neurophysiol. 2003 Feb;89(2):1150-60
12574488
J Physiol. 2005 Nov 15;569(Pt 1):291-304
16166163
Trends Neurosci. 2007 Jul;30(7):357-64
17532060
J Neurosci. 2003 Mar 1;23(5):1916-23
12629196
Brain Struct Funct. 2012 Apr;217(2):613-66
22179107
J Cogn Neurosci. 2004 Nov;16(9):1484-92
15601513
Neurosignals. 2011;19(3):151-62
21757872
J Neurosci Methods. 2008 Mar 30;169(1):141-57
18242715
Mov Disord. 2010 Apr 15;25(5):578-86
20213817
Front Syst Neurosci. 2013 Nov 26;7:98
24324412
Nat Rev Neurosci. 2012 May 18;13(6):407-20
22595786
J Neurol. 2009 Aug;256(8):1321-9
19363633
J Neurosci. 2013 Feb 6;33(6):2268-80
23392658
PLoS One. 2013;8(3):e59839
23555799
Neuroscience. 1998 Mar;83(1):107-21
9466402
Mov Disord. 2015 Nov;30(13):1750-8
26360123
Cereb Cortex. 2009 May;19(5):1055-63
18787234